Novartis Ag

Thomas Anthony Hunt

Catherine Howsham

Stephen Paul Collingwood

Peter Hunt

Andrew Dunstan

Lee Edwards

Nichola Smith

Emma Budd

Gurdip Bhalay

Paul Joseph Oakley

Graham Charles Bloomfield

Peter Gedeck

Ian Bruce

Thomas Ullrich

Darren Mark Legrand

James Dale

Nicholas James Devereux

Andrew John Eatherton

Amarylla Horvath

Bernard Christophe Barlaam

Kurt Gordon Pike

Paul Oakley

A compound of Formula I in free or salt or solvate form, where R, R, R, R, R, R, R, R, R, Rand Rhave the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives

A compound of Formula I in free or salt or solvate form, where R, R, R, R, R, R, R, Rand Rhave the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases

The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R, R, Ar', A and B are defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

Organic compounds

A compound of Formula I or a hydrate or solvate thereof, where R, R, R, R, R, R, R, R, R, and Rhave the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Pyrazine derivatives as ENAC blockers

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel

Growing community of inventors

Horsham, United Kingdom

Thomas Anthony Hunt